Related Experiment Videos
Sch-27899 (Schering-Plough Corp)
1Department of Haematology, University Hospital Gasthuisberg, KU Leuven, Herestraat 49, Leuven 3000, Belgium. johan.maertens@kuleuven.ac.be
Idrugs : the Investigational Drugs Journal
|September 13, 2005
Summary
Sch27899 (Ziracin) is an investigational oligosaccharide antibiotic for Gram-positive bacterial infections. A cyclodextrin complex formulation is being developed to overcome toxicity issues and advance clinical trials.
Area of Science:
- Microbiology
- Pharmacology
- Medicinal Chemistry
Background:
- Sch27899 (Ziracin) is an oligosaccharide antibiotic belonging to the everninomicin class.
- It is derived from Micromonospora and shows potential against Gram-positive bacteria.
- Existing treatments face challenges with resistant strains like vancomycin-resistant and methicillin-resistant bacteria.
Purpose of the Study:
- To evaluate Sch27899 (Ziracin) as a novel therapeutic agent for Gram-positive bacterial infections.
- To address the limitations of current treatments against resistant bacterial strains.
- To develop a safer and more effective formulation of Sch27899 through a cyclodextrin complex.
Main Methods:
- Isolation of Sch27899 from Micromonospora.
- Development of a cyclodextrin complex to mitigate toxicity.
- Phase III clinical trials for efficacy and safety evaluation.
Main Results:
- Sch27899 demonstrates activity against challenging Gram-positive pathogens.
- The cyclodextrin complex formulation successfully overcomes previously observed toxicity issues.
- Ongoing phase III trials are assessing its clinical utility.
Conclusions:
- Sch27899 (Ziracin) represents a promising new antibiotic candidate for resistant Gram-positive infections.
- The novel cyclodextrin complex formulation enhances its therapeutic potential.
- Further clinical evaluation is expected to confirm its role in combating bacterial resistance.